CONTEXT: The ability to correlate MR and CT results with genomic information captured with gene array technology would be an important step toward integrating both sets of diagnostic data into clinical decision making. Dr. Michael Kuo and colleagues at the University of California, San Diego compared the genomic topography of tumors mapped by complementary DNA (cDNA) microarrays with functional patterns seen with contrast-enhanced CT and MR imaging. They found that cross-sectional imaging can potentially reveal genomic patterns in renal cell carcinoma.
RESULTS: Renal tumors from 27 patients were examined with cDNA microarrays containing 23,000 elements representing 17,000 human genes, of which more than 7000 have been characterized. Of these 23,000 gene fragments, called clones, Kuo selected 1550 for analysis based on variations in their expression. The pattern of gene expression variation for each clone was plotted on a heat map covering each renal tumor. MRI and contrast-enhanced CT identified the presence or absence of hemorrhage or necrosis and characterized enhancement patterns. The patterns of enhancement and necrosis demonstrated significant correlation (p
IMAGE: A heat map of gene expression (top) tracks gene expression in a renal tumor. Red signifies gene overexpression, and green shows where the genes are underexpressed. A contrast-enhanced coronal MR image of a large renal tumor (bottom) reveals necrosis that corresponded to changes in gene expression.
IMPLICATIONS: Conventional CT and MR can potentially characterize large-scale gene regulation associated with specific biological processes. Such imaging traits may reveal early information concerning the response to cancer therapy.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.